Endocrine Abstracts

Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit. The close clinical and temporal relationships between Graves’ hyperthyroidism and GO suggest that both conditions derive from a single systemic process and share the thyrotropin receptor (TSHR) as autoantigen. Autoimmunity directed against the TSHR on orbital fibroblasts sets in motion connective tissue remodeling within the orbit that leads to the various clinical expressions of the diseas...

Around 50% of patients with Graves’ disease (GD) have Graves’ orbitopathy (GO). However, only 5–10% have overt active disease which merits more than symptomatic treatment. Clearly, the best treatment is prophylaxis related to avoiding tobacco smoking and to obtain and maintain euthyroidism.Whether antithyroid drugs (ATDs), radioiodine (RAI), or thyroidectomy should be chosen for therapy of GD, whether or not there is presence of active GO,...

Management of Graves’ orbitopathy (GO) is a challenge, and 30–50% of patients are eventually dissatisfied with medical treatment outcome. GO natural history is poorly understood, but some patients experience a progression of GO over time. Thus, prevention of development/progression by abolishing risk factors (e.g. smoking, thyroid dysfunction) is important. The recent results of a randomized clinical trial (RCT) carried out by the EUGOGO group showed that selenium (s...